First-in-Human Telerobotic Coronary Intervention Procedures Published in EClinicalMedicine

September 3, 2019 — Corindus Vascular Robotics Inc. announced that EClinicalMedicine, a clinical journal published by The Lancet, has published the results from the Telerobotic Intervention Study, the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catheterization lab. The study was conducted using Corindus’ CorPath technology platform.

The paper, titled Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience, discusses five successful patient cases performed by Tejas Patel, M.D., chairman and chief interventional cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India. The five patients featured in the paper underwent elective PCI procedures from a distance of approximately 20 miles (32 kilometers) from Patel’s location inside the Swaminarayan Akshardham temple in Gandhinagar, Gujarat, India. His partner, Sanjay Shah, M.D., was onsite in the room with each patient at the Apex Heart Institute.

“I am honored to have been a part of this medical milestone,” stated Patel. “The application of telerobotics for remote treatment has the potential to impact a significant number of lives by providing access to specialized care that may not otherwise be possible. I am pleased to share my experience with the clinical community in such a well-respected publication that is part of the Lancet family,” added Patel.

Corindus developed the remote telerobotic interventional platform to deliver highly specialized and timely cardiovascular care to underserved patient populations with geographic barriers to treatment. The company is working on product development to enable use of the CorPath System in remote interventions and expand the company’s robotic platform to address stroke care.

For more information: www.corindus.com

Reference

1. Patel T.M., Shah S.C., Pancholy S.B. Long Distance Tele-Robotic-Assisted Percutaneous Coronary Intervention: A Report of First-in-Human Experience. EClinicalMedicine, published online Sept. 3, 2019. https://doi.org/10.1016/j.eclinm.2019.07.017

Related Content

$An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.$

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021

Quantitative Flow Ratio (QFR) Study Looks at Impact on Appropriateness of Revascularization in the PIONEER-IV Trial

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of

ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.

News | Cath Lab | July 14, 2021

FDA Clears SafeCross Transseptal RF Puncture and Steerable Balloon Introducer System

July 13, 2021 — East End Medical announced it received U.S.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor

Creating a Cardio-renal Program to Expand Patient Volume

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021

Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor

SCAI 2021 Late-breaking Clinical Study Results

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from

Videos | Cath Lab | May 05, 2021

VIDEO: Avoiding Higher Risk Cath Lab Patients May Not Improve Outcomes Scores

Ashwin Nathan M.D.

Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021

Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta

New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell

News | Cath Lab | April 29, 2021

Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors

April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images

News | Cath Lab | April 28, 2021

COVID Caused Major Decline in Heart Attack Patients Seeking Care

April 28, 2021 – Results from a retrospective observational study, presented today at...

A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021

SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document

April 28, 2021 — The Society for Cardiovascular Angiography and Intervent...